The Effect of Prophylactic Administration of Ketorolac Ophthalmic Suspension on Prevention of Surgically Induced Miosis in Patients Undergoing Cataract Surgery
Background: Cataract extraction surgery remains the most commonly performed eye surgery by ophthalmologists. The maintenance of mydriasis is required throughout surgery to allow better visualization of the surgical field and a greater working space within the center of the eye. Non-steroidal anti-inflammatory agents (NSAIDs) have their effect in maintaining mydriasis by their ability to inhibit prostaglandin synthesis.
Methods: This was a prospective, randomized clinical trial study in 84 patients undergoing phacoemulsification cataract surgery. Patients were randomized to ketorolac tromethamine 0.5% (n=42) or the control group (n=42). Patients in the ketorolac group received one drop of ketorolac every 15 min for a total of 4 drops from one hour before surgery. The horizontal diameters of the pupil were measured in millimeters with a caliper under the microscope at the following stages: before surgery, after intracameral epinephrine injection, after nuclear emulsification and at the end of surgery.
Results: The difference in pupillary diameter at the end of surgery was statistically significant between two groups (7.34 ± 1.0 mm and 8.01 ±0.67 mm in the control and the ketorolac groups, respectively; p=0.018). The difference in mean pupil size after intracameral epinephrine injection and after nuclear emulsification between the control group (0.51 ± 0.25 mm) and the ketorolac group (0.01 ± 0.20 mm) was statistically significant (p <0.001). Moreover, the difference in mean pupil size after intracameral epinephrine injection and at the end of surgery between the control group (0.79 ± 0.44 mm) and the ketorolac group (0.19 ± 0.23 mm) was statistically significant (p <0.001). There was no difference in maintaining mydriasis between diabetic patients and non-diabetic patients.
Conclusion: Topical ketorolac is an effective inhibitor of miosis during phacoemulsification cataract surgery, and provides a more stable mydriatic effect throughout the surgical procedure.
Uhr BW. History of ophthalmology at Baylor University Medical Center. Proc (Bayl Univ Med Cent). 2003; 16(4): 435-8.
Brian G, Taylor H. Cataract blindness--challenges for the 21st century. Bull World Health Organ. 2001; 79(3):249-56.
Linebarger EJ, Hardten DR, Shah GK, Lindstrom RL. Phacoemulsifi cation and modern cataract surgery. Surv Ophthalmol. 1999; 44(2):123-47.
Camras CB, Miranda OC. The putative role of prostaglandins in surgical miosis. Prog Clin Biol Res. 1989; 312:197-210.
Podos SM. Prostaglandins, nonsteroidal anti-infl ammatory agents and eye disease. Trans Am Ophthalmol Soc. 1976; 74:637-60.
Neal MJ. Medical Pharmacology at a Glance. 4th ed. Oxford: Blackwell Science; 2002.
Yospaiboon Y, Luanratanakorn P, Noppawinyoowong C. Randomized double blind study of phenylephrine 2.5% vs 10% on pupillary dilation. J Med Assoc Thai. 2004; 87(11):1380-4.
Stavert B, Mcguinness MB, Harper CA, Guymer RH, Finger RP. Cardiovascular adverse effects of phenylephrine eyedrops: a systematic review and meta-analysis. JAMA Ophthalmol. 2015; 133(6):647-52.
Narváez J, Kronberg BP, Park H, Zumwalt JR, Wong B, Bacon G, et al. Pupil dilation using a standard cataract surgery regimen alone or with atropine 1.0% pretreatment: prospective comparative evaluation. J Cataract Refract Surg. 2010; 36(4): 563-7.
Flach AJ, Dolan BJ, Donahue ME, Faktorovich EG, Gonzalez GA. Comparative effects of ketorolac 0.5% or diclofenac 0.1% ophthalmic solutions on infl ammation after cataract surgery. Ophthalmology. 1998; 105(9):1775-9.
Grob SR, Gonzalez-Gonzalez LA, Daly MK. Management of mydriasis and pain in cataract and intraocular lens surgery: review of current medications and future directions. Clin Ophthalmol 2014; 8:1281-9.
Hovanesian JA, Sheppard JD, Trattler WB, Gayton JL, Malhotra RP, Schaaf DT, et al. Intracameral phenylephrine and ketorolac during cataract surgery to maintain intraoperative mydriasis and reduce postoperative ocular pain: Integrated results from 2 pivotal phase 3 studies. J Cataract Refract Surg. 2015; 41(10):2060-8.
Ke TL, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular infl ammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000; 24(4):371-84.
Lindstrom R, Kim T. Ocular permeation and inhibition of retinal infl ammation: an examination of data and expert opinion on the clinical utilityof nepafenac. Curr Med Res Opin. 2006; 22(2):397–404.
Solomon KD, Turkalj JW, Whiteside SB, Stewart JA, Apple DJ. Topical 0.5% ketorolac vs 0.03% fl urbiprofen for inhibition of miosis during cataract surgery. Arch Ophthalmol. 1997; 115(9):1119-22.
Shaikh MY, Mars JS, Heaven CJ. Prednisolone and fl urbiprofen drops to maintain mydriasis during phacoemulsifi cation cataract surgery. J Cataract Refract Surg. 2003; 29(12):2372-7.
Zanetti FR, Fulco EA, Chaves FR, da Costa Pinto AP, Arieta CE, Lira RP. Effect of preoperative use of topical prednisolone acetate, ketorolac tromethamine, nepafenac and placebo, on the maintenance of intraoperative mydriasis during cataract surgery: a randomized trial. Indian J Ophthalmol 2012; 60(4):277-81.
Nikeghbali A, Falavarjani KG, Kheirkhah A, Bakhtiari P, Kashkouli MB. Pupil dilation with intracameral lidocaine during phacoemulsification. J Cataract Refract Surg 2007; 33(1):101-3.
Myers WG, Shugar JK. Optimizing the intracameral dilation regimen for cataract surgery: prospective randomized comparison of 2 solutions. J Cataract Refract Surg. 2009; 35(2):273-6.
Akman A, Yilmaz G, Oto S, Akova YA. Comparison of various pupil dilation methods for phacoemulsification in eyes with a small pupil secondary to pseudoexfoliation. Ophthalmology. 2004; 111:1693-8.
Porela-Tiihonen S, Kaarniranta K, Kokki M, Purhonen S, Kokki H. A prospective study on postoperative pain after cataract surgery. Clin Ophthalmol. 2013; 7:1429-35.
Narv aez J, Kronberg BP, Park H, Zumwalt JR, Wong B, Bacon G, et al. Pupil dilation using a standard cataract surgery regimen alone or with atropine 1.0% pretreatment; prospective comparative evaluation. J Cataract Refract Surg. 2010; 36(4):563-7.
Arshinoff SA, Opalinski YA. The pharmacotherapy of cataract surgery. In: Yanoff M, Duker JS, eds, Ophthalmology, 3rd ed. Philadelphia, PA, Mosby Elsevier, 2009; 434–440.
Joshi RS. Pre-operative use of the topical steroidal and non-steroidal anti-inflammatory agents to maintain intra-operative mydriasis during cataract surgery. Indian J Ophthalmol. 2013 May; 61(5):246-7.
Grob SR, Gonzalez-Gonzalez LA, Daly MK. Management of mydriasis and pain in cataract and intraocular lens surgery: review of current medications and future directions. Clin Ophthalmol. 2014; 8:1281-9.
Lawuyi LE, Gurbaxani A. The clinical utility of new combination phenylephrine/ketorolac injection in cataract surgery. Clin Ophthalmol. 2015; 9:1249-54.
Copyright (c) 2016 Archives of Anesthesiology and Critical Care
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.